The B-team: Equal but different?

1 Chaplin S, Birkedal MF, Crilly E, et al. Haemophilia specialist nurses’ perceptions of haemophilia B. J Haem Pract 2021; 8(1): 119–127. doi: 10.2478/jhp-2021-0013. ChaplinS BirkedalMF CrillyE Haemophilia specialist nurses’ perceptions of haemophilia B J Haem Pract 2021 8 1 119 127 10.2478/jhp-2021-0013 Open DOISearch in Google Scholar

2 Garner K, Guelcher C, Pollard D. The use of rIX-FP in patients with haemophilia B: A nurses’ perspective. J Haem Pract 2021; 8(1): 86–97. doi: 10.17225/jhp00180. GarnerK GuelcherC PollardD The use of rIX-FP in patients with haemophilia B: A nurses’ perspective J Haem Pract 2021 8 1 86 97 10.17225/jhp00180 Open DOISearch in Google Scholar

3 Murphy SL, High KA. Gene therapy for haemophilia. Br J Haematol 2008; 140(5): 479–87. doi: 10.1111/j.1365-2141.2007.06942.x. MurphySL HighKA Gene therapy for haemophilia Br J Haematol 2008 140 5 479 87 10.1111/j.1365-2141.2007.06942.x 240864118275425 Open DOISearch in Google Scholar

4 UCL research leads to haemophilia gene therapy success. 15 December 2017. UCL. Available at https://www.ucl.ac.uk/news/2017/dec/ucl-research-leads-haemophilia-gene-therapy-success (accessed 27 September 2021). UCL research leads to haemophilia gene therapy success 15 December 2017 UCL Available at https://www.ucl.ac.uk/news/2017/dec/ucl-research-leads-haemophilia-gene-therapy-success (accessed 27 September 2021). Search in Google Scholar

5 Mann DM, Stafford KA, Poon MC, Matino D, Stafford DW. The Function of extravascular coagulation factor IX in haemostasis. Haemophilia 2021; 27(3): 332–339. doi: 10.1111/hae.14300. MannDM StaffordKA PoonMC MatinoD StaffordDW The Function of extravascular coagulation factor IX in haemostasis Haemophilia 2021 27 3 332 339 10.1111/hae.14300 33780107 Open DOISearch in Google Scholar

6 Castaman G. The benefits of prophylaxis in patients with hemophilia B. Expert Rev Hematol 2018; 11(8): 673–683. doi: 10.1080/17474086.2018.1489719. CastamanG The benefits of prophylaxis in patients with hemophilia B Expert Rev Hematol 2018 11 8 673 683 10.1080/17474086.2018.1489719 29909699 Open DOISearch in Google Scholar

7 Srivastava A, Santagostino E, Dougall A, et al.; WFH Guidelines for the Management of Hemophilia panellists and co-authors. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020; 26 Suppl 6: 1–158. doi: 10.1111/hae.14046. SrivastavaA SantagostinoE DougallA WFH Guidelines for the Management of Hemophilia panellists and co-authors WFH Guidelines for the Management of Hemophilia, 3rd edition Haemophilia 2020 26 Suppl 6 1 158 10.1111/hae.14046 32744769 Open DOISearch in Google Scholar

8 Valentino L, Blanchett V, Negrier C, et al. Personalising haemophilia management with shared decision making. J Haem Pract 2021; 8(1): 69–79. doi: 10.17225/jhp00178. ValentinoL BlanchettV NegrierC Personalising haemophilia management with shared decision making J Haem Pract 2021 8 1 69 79 10.17225/jhp00178 Open DOISearch in Google Scholar

9 Nathwani AC, Reiss UM, Tuddenham EG, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014; 371(21): 1994–2004. doi:10.1056/NEJMoa1407309. NathwaniAC ReissUM TuddenhamEG Long-term safety and efficacy of factor IX gene therapy in hemophilia B N Engl J Med 2014 371 21 1994 2004 10.1056/NEJMoa1407309 427880225409372 Open DOISearch in Google Scholar

10 Von Drygalski A, Giermasz A, Castaman G, et al. Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. Blood Adv 2019; 3(21): 3241–3247. doi: 10.1182/bloodadvances.2019000811. Von DrygalskiA GiermaszA CastamanG Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B Blood Adv 2019 3 21 3241 3247 10.1182/bloodadvances.2019000811 685510131698454 Open DOISearch in Google Scholar